ALOXI® Provides Powerful CINV Prevention that Can't Be Ignored
Indication
ALOXI
® (palonosetron HCl) injection 0.25 mg is indicated
in adults for the prevention of acute and delayed nausea
and vomiting associated with initial and repeat courses
of moderately emetogenic chemotherapy, and acute nausea
and vomiting associated with initial and repeat courses of highly emetogenic chemotherapy.
Important Safety Information
- ALOXI is contraindicated in patients known to have hypersensitivity to the drug
or any of its components
- Most commonly reported adverse reactions in chemotherapy-induced
nausea and vomiting include headache (9%) and constipation (5%)
FOR MORE INFORMATION ABOUT ALOXI SEE FULL PRESCRIBING INFORMATION.
ALOXI is available by prescription only.
References:
- Gralla R, Lichinitser M, Van der Vegt S, et al. Palonosetron improves
prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic
chemotherapy: results of a double-blind randomized phase III trial comparing single
doses of palonosetron with ondansetron. Ann Oncol. 2003;14:1570-1577.
- Eisenberg P, Figueroa-Vadillo J, Zamora R, et al. Improved prevention
of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron,
a pharmacologically novel 5-HT3 receptor antagonist: results of a phase
III, single-dose trial versus dolasetron. Cancer. 2003;98:2473-2482.
- Data on file. Eisai Inc., Woodcliff Lake, NJ.
- Aapro MS, Grunberg SM, Manikhas GM, et al. A phase III, double-blind,
randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced
nausea and vomiting following highly emetogenic chemotherapy. Ann Oncol.
2006;17:1441-1449.